More Palestinians killed in new wave of Gaza strikes
Mourners react near the body of a Palestinian child killed in an Israeli strike, in Gaza City
By Nathan MorleyAt least 81 Palestinians were killed in Israeli airstrikes across Gaza over a 24-hour period, according to Gaza health officials, as Israeli forces targeted areas where displaced civilians were sheltering.
The strikes hit a tent camp near a stadium in Gaza City and a school in the Tuffah neighbourhood, authorities said. Among the dead were children and entire families. Gaza's Health Ministry said more than 56,400 Palestinians have been killed since the war began in October 2023.
The surge in casualties has intensified international calls for a ceasefire, with diplomatic efforts reportedly ongoing involving U.S. and Qatari mediators.
The Israeli military earlier said it had killed one of the founding members of Hamas.
Israel resumed large-scale military operations in Gaza in early March. Since then, at least 6,050 Palestinians have been killed and more than 21,000 wounded, bringing the total number of injuries since the beginning of the war to over 133,000, according to Gaza-based officials.
Iran uranium enrichment programme
In a separate development, the head of the U.N. nuclear watchdog said Iran could resume uranium enrichment within months.
International Atomic Energy Agency Director General Rafael Grossi said last week's airstrikes damaged nuclear infrastructure but did not cause total destruction.
Grossi's comments appeared to contradict U.S. claims that Iran's nuclear capabilities had been significantly set back.--Vatican News
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BusinessToday
2 hours ago
- BusinessToday
Solution Group To Distribute Cervical Cancer Vaccine In Malaysia
Solution Group Berhad announced through an exclusive international distribution agreement with China-based Xiamen Innovax Biotech Co., Ltd. for the supply of INNOVAX's recombinant Human Papillomavirus (HPV) Bivalent Vaccine, Cecolin. This collaboration marks a strategic move for SGB into the biologics and vaccine distribution sector, complementing its existing healthcare initiatives. INNOVAX is a prominent biotechnology company specialising in the development, manufacturing, and marketing of innovative vaccines. Headquartered in Xiamen, China, INNOVAX is known for its unique Escherichia coli -based recombinant vaccine system. This platform was instrumental in the development of the world's first Hepatitis E Vaccine, Hecolin®, launched in China in 2012, and its Cervical Cancer Vaccine, Cecolin (HPV16&18 bivalent), approved in 2019. Under the terms of the exclusive distribution agreement, SOLBIO is granted the rights to register, import, commercialise, and distribute Cecolin in Malaysia. Key highlights of the agreement include minimum order quantity commitments for three years after product registration, with SOLBIO also responsible for regulatory registration, import licensing, and pharmacovigilance. Both companies will jointly work on ensuring cold chain logistics compliance, market development, and product education. The agreement commenced on July 1, 2025, and has an initial term of three years, with potential for renewal. Cecolin, developed using Escherichia coli expression technology, is designed for the prevention of cervical cancer. The vaccine has notably received prequalification from the World Health Organization (WHO), signifying its adherence to global standards of quality, safety, and efficacy. Related
New Straits Times
5 hours ago
- New Straits Times
More investors flocking to 'stable' Europe
PETER Roessner is feeling both sides of United States President Donald Trump's trade war. While tariff risks mean the chief executive officer of Luxembourg-based hydrogen firm H2Apex can no longer rely on US suppliers for its more than €200 million project in Lubmin, Germany, investor interest in European projects is rising. "Investors in the hydrogen sector are now focusing more on the European market due to the absolute uncertainty and planning insecurity in the US," he said, adding that this included both local and US players. "The framework conditions in Europe are not ideal, but they are stable." Roessner's comments are indicative of a trend that has taken hold in recent months: Investors and companies are increasingly turning to Europe, drawn by an infrastructure- and defence-led spending push that offers stability at a time when Trump's erratic tariff policies have made the US market a less safe bet, according to more than a dozen interviews with executives and fund managers. The shift has also been fuelled by Trump's tendency to make sweeping tariff threats and announcements that are then often delayed or changed, and to draw up executive orders that have tested the limits of his presidential power. "The US is coming from a very capital market-friendly and stable environment. Now, there is political intervention and also an attempt to expand power," said Christoph Witzke, who heads the CIO office at Deka, one of Germany's largest investment funds. "This creates uncertainty that some kind of intervention ... could come at any time," he said, adding that Europe had become the centre of attention in the most recent investor conferences as a result. With a July 9 deadline for a trade deal less than two weeks away — and Trump saying he will impose 50 per cent tariffs on all European Union goods without a deal — investors have started shifting their money. Data from LSEG's Lipper Funds show that more than US$100 billion has flowed into European equity funds so far this year — up threefold from the same period last year — while outflows from the US more than doubled to nearly US$87 billion. "All that is an indication that at least market forces, investors, those who move real money around, actually see value and have confidence in Europe," said European Central Bank president Christine Lagarde earlier this month. This shift in focus was also illustrated by the weak market debut of Holcim's North American spin-off Amrize late last month, which was announced to much fanfare in early 2024 at a time when the lure of US valuations also got some of its rivals excited. In contrast, the share price of Holcim itself, now squarely focused on Europe, Latin America and North Africa, soared 15 per cent. Siemens Energy, which makes more than a fifth of its sales in the US, has noted a shift in sentiment, said finance chief Maria Ferraro, on the back of a recent US roadshow and an 84 per cent rise in the group's share price year-to-date. Apart from the improved market view, more investments are also crucial in efforts to revive the EU's economy and narrow its competitiveness gap compared with other regions, most notably China and the US. Closely watched foreign direct investment flows into Germany, the bloc's largest economy, more than doubled to €46 billion in the first four months of 2025, according to the most recent data from the Bundesbank, marking the highest level since 2022. It also shows that German companies even pulled money out of the US in three of the first four months of the year, with their balance of foreign direct investments in April at a negative €2.38 billion. Negative balances emerge when companies either divest more than they invest in a foreign country or decide against extending credit lines to local counterparts. But the picture is not all rosy, with several investors pointing out that Europe is now under pressure to act faster, create better regulation and make good on its spending pledges. "This sentiment can quickly turn again. This should be both a warning and an incentive to use the momentum now and consistently implement the planned agenda," said Stefan Wintels, head of German state-backed lender KfW.
Malaysian Reserve
6 hours ago
- Malaysian Reserve
Solution Group inks exclusive deal to distribute HPV vaccine Cecolin in Malaysia
SOLUTION Group Bhd (SGB), through its wholly-owned subsidiary Solution Biologics Sdn Bhd (SOLBIO), has signed an exclusive distribution agreement with China-based Xiamen Innovax Biotech Co Ltd (INNOVAX) to register, commercialise and distribute the Cecolin Human Papillomavirus (HPV) vaccine in Malaysia. Under the agreement, SOLBIO will hold exclusive rights to register, import, promote and market Cecolin, a recombinant HPV bivalent vaccine targeting HPV types 16 and 18 – the primary causes of cervical cancer – for women aged 9 to 45 years. The vaccine, produced using Escherichia coli expression technology, has a 36-month shelf life and meets World Health Organization (WHO) prequalification standards. 'This partnership with INNOVAX is a major step forward for SOLBIO in expanding our vaccine portfolio and supporting public health efforts in Malaysia,' said SGB's group CEO Datuk Mohd Nazlee Kamal. 'Cecolin provides a cost-effective and globally recognized solution to HPV prevention, and we are proud to make it accessible to our communities,' he added. 'We believe this partnership will drive greater vaccine accessibility and cervical cancer prevention in the region,' INNOVAX GM Huirong Pan said. The agreement follows a series of discussions between both parties aimed at strengthening healthcare outcomes through access to high-quality, affordable vaccines. — TMR
